Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Triflepig, Even IF liver toxicity is a substantive issue after further investigation (which IS needed to confirm or otherwise), lots of theraputics cause liver problems yet the risk/reward ratio keeps them on the market. AND, yes, all sorts of technology/biology changes could make Iclaprim valuable.
No I agree and I think I even said words to that effect in the original post. It’s a risky one but you know how it goes risk/reward ..... I just think this one is leaning in our favour right now. But even then it could all change in the blink of an eye I accept that and am more than happy to hold on that basis.
Mark, I understand. It's just that I wouldn't want people to be persuaded by the claims, not yours, that the future is necessarily the same as the past.
“ While I appreciate the time and effort that goes into the history lesson (by both posters) that is Iclaprim, I do feel the need to point out that the past is pretty irrelevant, especially in the world of biotech, ”
I appreciate the world of bio tech is fast moving but I’m looking more at the rto process and apart from some rule changes along the way the mechanics of that remain a constant. Iclaprim sale/inclusion is a bonus.
Not yet. Though they probably will one day, by phage I would imagine.
Hi Jackdaw, I may have misunderstood your post.
I interpreted it that you were saying that iclaprim has been superseded by a newer form of biotech?
B1ll, I'd reply but I genuinely don't know what you mean.
@jackdaw.....forget the history lesson, could you please give me a science tutorial to explain why iclaprim is out dated?.
Look at anti-biotics......have they really evolved?
While I appreciate the time and effort that goes into the history lesson (by both posters) that is Iclaprim, I do feel the need to point out that the past is pretty irrelevant, especially in the world of biotech, where altered circumstances can turn things on a sixpence. Those looking to the past are like nineteenth century investors buying animal-fat candles, not believing that mineral oils are about to shake the world of heat and light. Or people in 2019 investing in retail properties. It's all about the future - that's what makes it a bit of a gamble.